BioCentury
ARTICLE | Clinical News

Milciclib: Ph I data

April 27, 2017 9:11 PM UTC

Data from 14 evaluable patients with refractory solid tumors in a Phase I trial showed that oral milciclib plus gemcitabine led to a disease control rate (DCR) of 36%, including 1 partial response in a patient with non-small cell lung cancer (NSCLC) and 4 cases of stable disease for up to 14 months. Milciclib was well tolerated with neutropenia and thrombocytopenia reported as the most common treatment-related adverse events. Patients received once-daily 45, 60 or 80 mg/m2 milciclib for 7 days on and 7 days off in each 4-week cycle. Data were published in Cancer Chemotherapy and Pharmacology...